39,850 Shares in BridgeBio Pharma (NASDAQ:BBIO) Bought by Maven Securities LTD

Share on StockTwits

Maven Securities LTD bought a new stake in shares of BridgeBio Pharma (NASDAQ:BBIO) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 39,850 shares of the company’s stock, valued at approximately $1,020,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of BBIO. Aisling Capital Management LP acquired a new stake in BridgeBio Pharma during the 2nd quarter worth about $103,449,000. JPMorgan Chase & Co. purchased a new position in BridgeBio Pharma during the second quarter valued at approximately $25,274,000. Janus Henderson Group PLC acquired a new position in BridgeBio Pharma in the second quarter valued at approximately $9,331,000. Artal Group S.A. acquired a new position in BridgeBio Pharma in the second quarter valued at approximately $5,394,000. Finally, TimesSquare Capital Management LLC acquired a new position in BridgeBio Pharma in the second quarter valued at approximately $4,046,000. Institutional investors own 85.33% of the company’s stock.

BBIO has been the topic of a number of analyst reports. Jefferies Financial Group began coverage on shares of BridgeBio Pharma in a research note on Monday, July 22nd. They set a “buy” rating and a $38.00 price objective on the stock. Goldman Sachs Group started coverage on shares of BridgeBio Pharma in a report on Monday, July 22nd. They set a “buy” rating and a $42.00 price target on the stock. Leerink Swann started coverage on shares of BridgeBio Pharma in a research report on Monday, July 22nd. They set an “outperform” rating and a $34.00 price target on the stock. Svb Leerink started coverage on shares of BridgeBio Pharma in a report on Monday, July 22nd. They issued an “outperform” rating and a $34.00 price objective for the company. Finally, Raymond James started coverage on shares of BridgeBio Pharma in a research report on Friday, July 26th. They issued an “outperform” rating and a $36.00 price objective for the company. Eight equities research analysts have rated the stock with a buy rating, BridgeBio Pharma presently has an average rating of “Buy” and an average price target of $40.13.

In related news, major shareholder Genetic Disorder L.P. Kkr bought 2,647,100 shares of the business’s stock in a transaction dated Monday, July 1st. The stock was acquired at an average price of $17.00 per share, with a total value of $45,000,700.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Brian C. Stephenson bought 55,500 shares of the business’s stock in a transaction dated Monday, July 1st. The shares were bought at an average cost of $17.00 per share, with a total value of $943,500.00. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 7,409,500 shares of company stock worth $125,947,930.

BBIO stock traded up $0.56 during mid-day trading on Wednesday, reaching $27.11. 12,391 shares of the company’s stock were exchanged, compared to its average volume of 160,613. The firm has a 50 day moving average of $28.81. BridgeBio Pharma has a 12-month low of $24.06 and a 12-month high of $32.94.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc finds, develops, and delivers various medicines for genetic diseases. The company has a pipeline of 15 development programs that include product candidates ranging from early discovery to late-stage development in various therapeutic areas, including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology.

Recommended Story: What is the downside to momentum investing?

Institutional Ownership by Quarter for BridgeBio Pharma (NASDAQ:BBIO)

Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.